Dean Davis April 11, 2023 No Comments THE LEAD COMPOUND, TRT-8174, is a novel and unique small synthetic chemical molecule designed to mimic the key three dimensional binding motif of MSF. Read More
Dean Davis April 11, 2023 No Comments Unlike other advanced wound care (AWC) medicines, MSF bioactives DO NOT INDUCE CELL PROLIFERATION. Read More
Dean Davis April 11, 2023 No Comments MSF bioactives show unprecedented POTENCY, eliciting half-maximal activity at femtomolar concentrations in tissue culture and promoting wound healing in vivo when using only 3-4 applications of picogram doses. Read More
Dean Davis April 11, 2023 No Comments SIGNAL TRANSDUCTION MECHANISMS show a clear distinction between MSF, which inhibits AKT activation on the target cells, and other factors used as AWC medicines, which commonly stimulate AKT activation. Read More
Dean Davis April 11, 2023 No Comments MSF bioactivity and expression is MODULATED BY THE EXTRACELLULAR MATRIX. This is relevant as it may be used to fine-tuning therapeutic intervention. Matrix modulation has not been reported for current AWC factors. Read More
Dean Davis April 11, 2023 No Comments MSF EXPRESSION MAY BE SWITCHED ON AND OFF in a reversible fashion. Read More
Dean Davis April 11, 2023 No Comments MSF bioactives INDUCE THE EXPRESSION OF ENDOGENOUS MSF PROTEIN by tissue cells. Read More
Dean Davis April 11, 2023 No Comments MANUFACTURING of TRT-8174 and other MSF mimetics is simple and inexpensive. Read More
Dean Davis April 11, 2023 No Comments APPLICATION. Presently available AWC biologics require prolonged and repeated applications at high concentrations. TRT-8174 may require a single or a very small number of applications at very low concentrations. Read More